Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Nature Medicine – In a pre-specified secondary analysis of the SELECT trial, once-weekly subcutaneous semaglutide 2.4 mg in patients with obesity was associated with a 22% reduction in the…